MX2021011923A - Novedoso derivado de azaindol. - Google Patents

Novedoso derivado de azaindol.

Info

Publication number
MX2021011923A
MX2021011923A MX2021011923A MX2021011923A MX2021011923A MX 2021011923 A MX2021011923 A MX 2021011923A MX 2021011923 A MX2021011923 A MX 2021011923A MX 2021011923 A MX2021011923 A MX 2021011923A MX 2021011923 A MX2021011923 A MX 2021011923A
Authority
MX
Mexico
Prior art keywords
sub
azaindole derivative
solvate
salt
novel azaindole
Prior art date
Application number
MX2021011923A
Other languages
English (en)
Inventor
Ayumu Okuda
Gen Watanabe
Toshiharu Morimoto
Akira Iwata
Hirotaka Sasaki
Takahisa Ogamino
Kosuke Usuda
Hiroyuki Ishiwata
Yuichiro Tabunoki
Keigo Nishii
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2021011923A publication Critical patent/MX2021011923A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Proporcionar un compuesto novedoso o una sal del mismo o un solvato del mismo, que tiene actividad inhibidora de CSF-1R y exhibe un efecto antitumoral; un derivado de azaindol de la fórmula (I): (ver Fórmula) en donde A representa un anillo arilo de C6-10, un heterociclo aromático, o un heterociclo insaturado, y A tiene opcionalmente un sustituyente o más sustituyentes iguales o diferentes; y R representa un grupo alquilo de C1-3 o un grupo heterocíclico saturado, o una sal del mismo o un solvato del mismo.
MX2021011923A 2019-03-29 2020-03-30 Novedoso derivado de azaindol. MX2021011923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068233 2019-03-29
PCT/JP2020/014475 WO2020203950A1 (ja) 2019-03-29 2020-03-30 新規アザインドール誘導体

Publications (1)

Publication Number Publication Date
MX2021011923A true MX2021011923A (es) 2021-11-03

Family

ID=72668977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011923A MX2021011923A (es) 2019-03-29 2020-03-30 Novedoso derivado de azaindol.

Country Status (10)

Country Link
US (1) US20220162206A1 (es)
EP (1) EP3950063A4 (es)
JP (1) JPWO2020203950A1 (es)
KR (1) KR20210146320A (es)
CN (1) CN113613729A (es)
BR (1) BR112021019050A2 (es)
CA (1) CA3134937A1 (es)
MX (1) MX2021011923A (es)
SG (1) SG11202109997PA (es)
WO (1) WO2020203950A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288918A (en) * 1992-09-29 1994-02-22 Union Carbide Chemicals & Plastics Technology Corporation Hydroformylation process
US5767321A (en) * 1995-12-06 1998-06-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
EP3209663B1 (en) * 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
CN107922396B (zh) * 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors

Also Published As

Publication number Publication date
JPWO2020203950A1 (es) 2020-10-08
CN113613729A (zh) 2021-11-05
BR112021019050A2 (pt) 2021-11-30
CA3134937A1 (en) 2020-10-08
EP3950063A1 (en) 2022-02-09
US20220162206A1 (en) 2022-05-26
SG11202109997PA (en) 2021-10-28
WO2020203950A1 (ja) 2020-10-08
KR20210146320A (ko) 2021-12-03
EP3950063A4 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
SG11201805286RA (en) α,β-UNSATURATED AMIDE COMPOUND
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
CR20210247A (es) Nuevos compuestos heterocíclicos
MX2020014116A (es) Agente profilactico o terapeutico para atrofia muscular espinal.
PH12021550400A1 (en) Cardiac sarcomere inhibitors
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
MX2022004127A (es) Compuestos heterociclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
MX2017002275A (es) Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk).
CR20220004A (es) Nuevos compuestos heterocíclicos
CY1122477T1 (el) Παραγωγα πυριδο-οξαζινονης ως αναστολεις tnap
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
NZ778087A (en) Pyrrolopyrimidine derivative and use thereof
MX2021011376A (es) Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
EA202091692A1 (ru) Амидинзамещенные бензоильные производные, пригодные в качестве гербицидов
EP4316504A3 (en) Compounds
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MX2021011923A (es) Novedoso derivado de azaindol.